CHICAGO TRUST Co NA Boosts Stake in Thermo Fisher Scientific Inc. $TMO

Key Points

• CHICAGO TRUST Co NA increased its stake in Thermo Fisher Scientific Inc. by 51.9%, now owning 1,916 shares worth $777,000 as of the end of the last quarter.
• Thermo Fisher reported $10.86 billion in revenue for the last quarter, surpassing the analysts' expectations, and set its Q3 2025 guidance for EPS between 5.460-5.510.
• The company announced a quarterly dividend of $0.43 per share, which is set to be paid on October 15th, with an annualized yield of 0.4%.

CHICAGO TRUST Co NA increased its position in Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 51.9% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,916 shares of the medical research company's stock after buying an additional 655 shares during the period. CHICAGO TRUST Co NA's holdings in Thermo Fisher Scientific were worth $777,000 at the end of the most recent quarter.

A number of other hedge funds also recently made changes to their positions in the company. Bernard Wealth Management Corp. purchased a new stake in Thermo Fisher Scientific during the fourth quarter valued at approximately $25,000. CBIZ Investment Advisory Services LLC raised its position in Thermo Fisher Scientific by 137.5% during the first quarter. CBIZ Investment Advisory Services LLC now owns 57 shares of the medical research company's stock valued at $28,000 after purchasing an additional 33 shares during the period. Ameriflex Group Inc. purchased a new stake in Thermo Fisher Scientific during the fourth quarter valued at approximately $30,000. Anderson Financial Strategies LLC purchased a new stake in Thermo Fisher Scientific during the first quarter valued at approximately $30,000. Finally, Keystone Global Partners LLC purchased a new stake in Thermo Fisher Scientific during the first quarter valued at approximately $31,000. 89.23% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, CAO Joseph R. Holmes sold 385 shares of the stock in a transaction on Friday, August 29th. The stock was sold at an average price of $492.63, for a total transaction of $189,662.55. Following the sale, the chief accounting officer owned 2,319 shares of the company's stock, valued at approximately $1,142,408.97. This trade represents a 14.24% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Gianluca Pettiti sold 400 shares of the stock in a transaction on Friday, July 25th. The shares were sold at an average price of $479.98, for a total value of $191,992.00. Following the sale, the executive vice president directly owned 22,367 shares in the company, valued at $10,735,712.66. This trade represents a 1.76% decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 30,066 shares of company stock valued at $14,182,963. 0.33% of the stock is currently owned by corporate insiders.

Thermo Fisher Scientific Stock Down 1.2%

Shares of NYSE:TMO opened at $469.41 on Wednesday. Thermo Fisher Scientific Inc. has a 52-week low of $385.46 and a 52-week high of $623.77. The stock has a market cap of $177.25 billion, a P/E ratio of 27.15, a price-to-earnings-growth ratio of 2.54 and a beta of 0.75. The business's 50 day moving average is $474.01 and its 200 day moving average is $448.70. The company has a quick ratio of 1.50, a current ratio of 1.93 and a debt-to-equity ratio of 0.65.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last announced its quarterly earnings data on Wednesday, July 23rd. The medical research company reported $5.36 earnings per share (EPS) for the quarter, topping the consensus estimate of $5.22 by $0.14. Thermo Fisher Scientific had a return on equity of 16.82% and a net margin of 15.24%.The company had revenue of $10.86 billion for the quarter, compared to analysts' expectations of $10.68 billion. During the same quarter in the prior year, the firm earned $5.37 earnings per share. Thermo Fisher Scientific's revenue was up 2.9% compared to the same quarter last year. Thermo Fisher Scientific has set its Q3 2025 guidance at 5.460-5.510 EPS. FY 2025 guidance at 22.220-22.840 EPS. Sell-side analysts predict that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current year.

Thermo Fisher Scientific Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Wednesday, October 15th. Shareholders of record on Monday, September 15th will be given a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a yield of 0.4%. The ex-dividend date of this dividend is Monday, September 15th. Thermo Fisher Scientific's dividend payout ratio (DPR) is 9.95%.

Analysts Set New Price Targets

A number of equities research analysts have issued reports on the company. Raymond James Financial restated an "outperform" rating and set a $535.00 price objective (up from $525.00) on shares of Thermo Fisher Scientific in a research report on Thursday, July 24th. Wall Street Zen downgraded Thermo Fisher Scientific from a "buy" rating to a "hold" rating in a report on Sunday, September 7th. Robert W. Baird increased their price target on Thermo Fisher Scientific from $553.00 to $567.00 and gave the stock an "outperform" rating in a report on Thursday, July 24th. William Blair began coverage on Thermo Fisher Scientific in a report on Monday, August 18th. They issued an "outperform" rating on the stock. Finally, Barclays upgraded Thermo Fisher Scientific from an "equal weight" rating to an "overweight" rating and increased their price target for the stock from $490.00 to $550.00 in a report on Thursday, September 11th. Sixteen analysts have rated the stock with a Buy rating and five have issued a Hold rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $588.35.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.